Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news


Gilead blockbuster nears Aust

Posted 14 December 2020

New prescription medicines including Gilead's potential arthritis blockbuster filgotinib have been scheduled by the TGA, hinting at their pending arrival on the Australian market.

The JAK1 inhibitor has had something of a rocky road in the US where it was knocked back by the FDA in August on toxicity concerns and ceased recruiting for a number of clinical trials in October.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Special Report
PBAC March agenda
Every major and minor sub sorted by indication
Special Report
Aust Covid Vaccine Tracker
UPDATE: Distribution of two mRNA vaccines overseas
Special Report
November 2020 PBAC outcomes
Just over half of submissions recommended